October 2, 2023 – Groombridge, Wu, Baughman & Stone successfully defended Novo Nordisk before the Patent Trial and Appeal Board against Mylan Pharmaceuticals in inter partes review (IPR) proceedings seeking to invalidate two Novo patents relating to its blockbuster semaglutide family of drugs, including Ozempic®, Wegovy®, and Rybelsus® (U.S. Patents Nos. 8,536,122 and 8,129,343).
The firm secured a significant victory by persuading the PTAB not to institute the challenges brought by Mylan on the ’343 and ’122 patents, which are two foundational patents covering semaglutide, the active ingredient in Ozempic®, Wegovy®, and Rybelsus®.
Ozempic®, Wegovy®, and Rybelsus® represent a new generation of science in metabolic therapies that is transforming treatment of both diabetes and obesity. Worldwide sales of these drugs have vaulted Novo Nordisk to its current position as the most valuable company in Europe by market cap. For example, according to market estimates, Ozempic is expected to generate $11 billion in revenues, while Wegovy earns $4 billion for Novo this year.
Partners J. Steven Baughman and Megan F. Raymond led the team.
The firm is also representing Novo in PTAB challenges brought by Mylan, Dr. Reddy’s Laboratories and Sun Pharmaceuticals to a patent concerning dosing of semaglutide, U.S. Patent No. 10,335,462.